Twist Bioscience (TWST) to Release Quarterly Earnings on Monday

Twist Bioscience (NASDAQ:TWST - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.56) per share and revenue of $92.00 million for the quarter. Twist Bioscience has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company's revenue for the quarter was up 24.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.75) EPS. On average, analysts expect Twist Bioscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Twist Bioscience Stock Performance

Shares of TWST stock traded up $0.01 on Thursday, hitting $38.33. The company's stock had a trading volume of 667,345 shares, compared to its average volume of 979,476. Twist Bioscience has a fifty-two week low of $30.32 and a fifty-two week high of $60.90. The company has a market capitalization of $2.29 billion, a PE ratio of -11.30 and a beta of 2.34. The stock's 50 day moving average is $39.34 and its 200-day moving average is $44.18. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Barclays reduced their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a report on Tuesday, February 4th. Guggenheim set a $50.00 price target on Twist Bioscience in a report on Friday, March 28th. Robert W. Baird raised their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. Finally, Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and an average price target of $52.80.

Insider Buying and Selling

In other Twist Bioscience news, COO Patrick John Finn sold 2,058 shares of the stock in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total transaction of $82,299.42. Following the completion of the sale, the chief operating officer now owns 265,460 shares of the company's stock, valued at approximately $10,615,745.40. This represents a 0.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Paula Green sold 918 shares of the company's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the sale, the senior vice president now directly owns 130,912 shares in the company, valued at $5,355,609.92. This trade represents a 0.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,432 shares of company stock worth $1,038,170 in the last ninety days. Company insiders own 3.01% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.